A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
The chain's origin can be traced to the Dwarf Grill (now the Dwarf House), a restaurant opened by S. Truett Cathy (the chain's former chairman and CEO) in 1946 in the Atlanta suburb of Hapeville, Georgia. The original store was located near the Ford Motor Company Atlanta Assembly Plant, a source of many of the restaurant's patrons for years. It was later remodeled, reopening in 2022. In 1961, after 15 years in the fast-food business, Cathy found a pressure fryer that could cook a chicken sandwich in the same time it took to cook a hamburger. Following this discovery, he registered the name Chick-fil-A, Inc. The company's trademarked slogan, "We Didn't Invent the Chicken, Just the Chicken Sandwich," refers to their flagship menu item, the Chick-fil-A chicken sandwich. Though Chick-fil-A was the first national chain to make a fast, fried chicken sandwich its flagship item, it has been shown that Cathy's claim to have "invented the chicken sandwich" is false. From 1964 to 1967, the sandwich was licensed to over fifty eateries, including Waffle House and the concession stands of the new Houston Astrodome. The Chick-Fil-A sandwich was withdrawn from sale at other restaurants when the first dedicated location opened in 1967, in the food court of the Greenbriar Mall in Atlanta. The chain expanded in the 1970s and early 1980s by opening new locations in suburban malls' food courts. The first freestanding location was opened April 16, 1986, on North Druid Hills Road in Atlanta, Georgia, and the company began to focus more on stand-alone units rather than food courts.
German literature can be traced back to the Middle Ages and the works of writers such as Walther von der Vogelweide and Wolfram von Eschenbach. Well-known German authors include Johann Wolfgang von Goethe, Friedrich Schiller, Gotthold Ephraim Lessing and Theodor Fontane. The collections of folk tales published by the Brothers Grimm popularised German folklore on an international level. The Grimms also gathered and codified regional variants of the German language, grounding their work in historical principles; their Deutsches Wörterbuch, or German Dictionary, sometimes called the Grimm dictionary, was begun in 1838 and the first volumes published in 1854. Influential authors of the 20th century include Gerhart Hauptmann, Thomas Mann, Hermann Hesse, Heinrich Böll, and Günter Grass. The German book market is the third-largest in the world, after the United States and China. The Frankfurt Book Fair is the most important in the world for international deals and trading, with a tradition spanning over 500 years. The Leipzig Book Fair also retains a major position in Europe.
Allergy/immunology Cardiology Cardiac electrophysiology Critical care medicine Endocrinology Gastroenterology Geriatrics Hematology/oncology Interventional cardiology Infectious diseases Nephrology Oncology Palliative care medicine Pulmonary Diseases Pulmonology Rheumatology Sleep medicine
Sources: en.wikipedia.org
==== Platelet-type ==== Platelet-type VWD (also known as pseudo-VWD) is an autosomal dominant genetic defect of the platelets. The VWF is qualitatively normal and genetic testing of the von Willebrand gene and VWF protein reveals no mutational alteration. The defect lies in the qualitatively altered GPIb receptor on the platelet membrane which increases its affinity to bind to the VWF. Large platelet aggregates and high molecular weight VWF multimers are removed from the circulation resulting in thrombocytopenia and diminished or absent large VWF multimers. The ristocetin cofactor activity and loss of large VWF multimers are similar to VWD type 2B.
The most common type of mineral tanning is chrome tanning, responsible for 85-90% of modern leather making. Chromium(III) sulfate ([Cr(H2O)6]2(SO4)3) has long been regarded as the most efficient and effective tanning agent. Chromium(III) compounds of the sort used in tanning are significantly less toxic than hexavalent chromium, although the latter arises in inadequate waste treatment. Chromium(III) sulfate dissolves to give the hexaaquachromium(III) cation, [Cr(H2O)6]3+, which at higher pH undergoes processes called olation to give polychromium(III) compounds that are active in tanning, being the cross-linking of the collagen subunits. The chemistry of [Cr(H2O)6]3+ is more complex in the tanning bath rather than in water due to the presence of a variety of ligands. Some ligands include the sulfate anion, the collagen's carboxyl groups, amine groups from the side chains of the amino acids, and masking agents. Masking agents are carboxylic acids, such as acetic acid, used to suppress formation of polychromium(III) chains. Masking agents allow the tanner to further increase the pH to increase collagen's reactivity without inhibiting the penetration of the chromium(III) complexes. Collagen is characterized by a high content of glycine, proline, and hydroxyproline, usually in the repeat -gly-pro-hypro-gly-. These residues give rise to collagen's helical structure. Collagen's high content of hydroxyproline allows cross-linking by hydrogen bonding within the helical structure. Ionized carboxyl groups (RCO2−) are formed by the action of hydroxide.
== Maturation and remodeling == When the levels of collagen production and degradation equalize, the maturation phase of tissue repair is said to have begun. During maturation, type III collagen, which is prevalent during proliferation, is replaced by type I collagen. Originally disorganized collagen fibers are rearranged, cross-linked, and aligned along tension lines. The onset of the maturation phase may vary extensively, depending on the size of the wound and whether it was initially closed or left open, ranging from approximately three days to three weeks. The maturation phase can last for a year or longer, similarly depending on wound type. As the phase progresses, the tensile strength of the wound increases. Collagen will reach approximately 20% of its tensile strength after three weeks, increasing to 80% after 12 months. The maximum scar strength is 80% of that of unwounded skin. Since activity at the wound site is reduced, the scar loses its red appearance as blood vessels that are no longer needed are removed by apoptosis. The phases of wound healing normally progress in a predictable, timely manner; if they do not, healing may progress inappropriately to either a chronic wound such as a venous ulcer or pathological scarring such as a keloid scar.
Sources: en.wikipedia.org
== Contraindications == Sodium hyaluronate has a very low incidence of side effects, however it is contraindicated in people who are sensitive to hyaluronate preparations. If being administered as an intra-articular injection, it should not be given when there are infections or skin disease at the injection site.
In Baze, the Supreme Court addressed whether Kentucky's particular lethal-injection procedure (using the standard three-drug protocol) comports with the Eighth Amendment; it also determined the proper legal standard by which lethal-injection challenges in general should be judged, all in an effort to bring some uniformity to how these claims are handled by the lower courts. Although uncertainty over whether executions in the United States would be put on hold during the period in which the United States Supreme Court considers the constitutionality of lethal injection initially arose after the court agreed to hear Baze, no executions took place during the period between when the court agreed to hear the case and when its ruling was announced, with the exception of one lethal injection in Texas hours after the court made its announcement. On April 16, 2008, the Supreme Court rejected Baze v. Rees, thereby upholding Kentucky's method of lethal injection in a majority 7–2 decision. Justices Ruth Bader Ginsburg and David Souter dissented. Several states immediately indicated plans to proceed with executions. The U.S. Supreme Court also upheld a modified lethal-injection protocol in the 2015 case Glossip v. Gross. By the time of that case, Oklahoma had altered its execution protocol to use midazolam instead of thiopental or pentobarbital; the latter two drugs had become unavailable for executions due to the European embargo on selling them to prisons.
Starmer pledges to give all veterans, young care leavers and victims of domestic abuse a "guaranteed roof over their head". Senedd members vote to withdraw proposals to require parties to ensure 50% of their candidates are women. 25 September – Unions win a nonbinding vote at the Labour Party Conference calling on the government to reverse its cuts to winter fuel payments. Former Conservative MP and government minister Michael Gove is appointed as editor of The Spectator, and will take up the post in early October. Conservative Senedd member Natasha Asghar is reprimanded by Senedd authorities for calling Wales' 20 mph speed limit a "blanket" policy on social media, while signing off a report advising her party to refrain from using the term. 26 September – Starmer and Foreign Secretary David Lammy hold their first meeting with Donald Trump, attending a two-hour dinner with the Republican presidential candidate in New York. Former Conservative Party chairwoman Baroness Saeeda Warsi resigns from the party in the House of Lords, saying it has lurched to the "far-right". 27 September – 2024 Scottish Conservatives leadership election: Russell Findlay is elected as the new leader of the Scottish Conservatives, succeeding Douglas Ross. The Senedd Commission forecasts it will need an extra £1.2m in 2025–26 to prepare for a larger Senedd at the 2026 election. 28 September – Rosie Duffield, MP for Canterbury, resigns from the Labour Party, citing what she describes as it "cruel" policies and Keir Starmer's "staggering hypocrisy" over his acceptance of gifts.
=== Occurrence in humans and the biosphere === Polonium-210 is widespread in the biosphere, including in human tissues, because of its position in the uranium-238 decay chain. Natural uranium-238 in the Earth's crust decays through a series of solid radioactive intermediates including radium-226 to the radioactive noble gas radon-222, some of which, during its 3.8-day half-life, diffuses into the atmosphere. There it decays through several more steps to polonium-210, much of which, during its 138-day half-life, is washed back down to the Earth's surface, thus entering the biosphere, before finally decaying to stable lead-206. As early as the 1920s, French biologist Antoine Lacassagne, using polonium provided by his colleague Marie Curie, showed that the element has a specific pattern of uptake in rabbit tissues, with high concentrations, particularly in liver, kidney, and testes. More recent evidence suggests that this behavior results from polonium substituting for its congener sulfur, also in group 16 of the periodic table, in sulfur-containing amino-acids or related molecules and that similar patterns of distribution occur in human tissues. Polonium is indeed an element naturally present in all humans, contributing appreciably to natural background dose, with wide geographical and cultural variations, and particularly high levels in arctic residents, for example.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.